During the past decade, MHAT "Lyulin", EAD conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 10 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MHAT "Lyulin", EAD" #1 sponsor was "Celgene" with 2 trials, followed by "Janssen Research & Development, LLC" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "R-Pharm International, LLC" with 2 trials sponsored and "Verona Pharma plc" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT "Lyulin", EAD" #1 collaborator was "OCT Clinical Trials" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "MHAT "Lyulin", EAD" are "Rheumatoid Arthritis" (4 trials), "Ulcerative Colitis" (3 trials), "Arthritis, Psoriatic" (1 trials), "COPD" (1 trials) and "Chronic Obstructive Pulmonary Disease" (1 trials). Many other conditions were trialed in "MHAT "Lyulin", EAD" in a lesser frequency.

Most popular intervention types in "MHAT "Lyulin", EAD" are "Drug" (16 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "RPC1063" (2 trials), "40 mg Laninamivir Octanoate" (1 trials), "80 mg Laninamivir Octanoate" (1 trials) and "AMT-101 (oral)" (1 trials). Other intervention names were less common.

The vast majority of trials in "MHAT "Lyulin", EAD" are 16 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "MHAT "Lyulin", EAD". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in MHAT "Lyulin", EAD, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in MHAT "Lyulin", EAD, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".